Intel (INTC) wants to re-invent itself. And the market appears to like what the company has planned. But are investors getting too optimistic and overlooking the level of execution Intel’s shift will require?
Vascular Biogenics (VBLT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.
Darden Restaurants (DRI) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $1.90 per share a year ago. These figures are adjusted for non-recurring items.
REX (REX) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.70 per share a year ago. These figures are adjusted for non-recurring items.
It is a tale of two pandemics as investors look to be buying into the reopening of the U.S. economy rather than worrying about the third wave of the coronavirus in Europe
It seems to be a wise idea to add Credit Acceptance Corporation CACC stock to your portfolio now. Strong fundamentals and good growth prospects make this stock a promising pick right now.The Zacks Consensus Estimate for the company’s current-year and next-year earnings has been
A disagreement took place between Treasury Secretary Janet Yellen and Senator Elizabeth Warren yesterday at the Senate Banking Committee hearing. Warren urged Yellen to designate the world’s largest asset manager as a systematically important financial institution (“SIFI”).
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are
In a concerted effort to maintain the authenticity of crucial information in today’s digital era, Telefonica, S.A.’s TEF subsidiary, Telefonica Tech, recently announced a partnership with Fibocom Wireless Inc. and aitos.io. Markedly, the collaboration focuses on amalgamating
Myovant Sciences Ltd. MYOV, along with partner Pfizer PFE, announced positive data from a late-stage study evaluating relugolix combination therapy (relugolix 40 mg plus estradiol 1 mg and norethindrone acetate 0.5 mg) for the treatment of uterine fibroids in women.
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
The stock price for Wayfair (NYSE:W), an e-commerce company that sells furniture and home goods, is up almost 12x from levels seen in mid-March 2020 when the broader markets made a bottom due to the spread of Covid-19. This marks a significant outperformance compared to the S&a
Texas Pacific Land (NYSE: TPL), a large landowner holding around 900k acres in oil-rich West Texas, has seen its stock rally by about 5x from around $310 on March 23, 2020 (when the broader markets made a bottom due to the spread of Covid-19) to about $1,580 currently. After a
Marriott Vacations Worldwide Corp stock (NYSE: VAC) has seen a spectacular rise of over 3.5x from its March 2020 lows, and at the current price of $174 per share the stock still seems to have some upside. Marriott Vacations Worldwide Corp offers vacation ownership, exchange, re
After a massive 3.4x rise from its March 2020 lows, at the current price of $372 per share, we believe that Deere & Company stock (NYSE:DE), appears to be fully valued. DE stock has rallied from $111 to $372 off the March 2020 bottom compared to the S&P which moved 75%.
Medtronic (NYSE: MDT) looks attractive at current levels of $117, as it is up 60% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks an underperformance compared to the S&P which has moved 75% since its
CarMax’s stock (NYSE: KMX) experienced a marginal loss over the last week (five trading days) to levels of around $132 currently. But will the company’s stock see higher levels over the coming weeks, or is a decline in the stock imminent? According to the Trefis Mac
We believe that Inovio Pharmaceuticals (NYSE: INO), a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, is a good buying opportunity at the present time. INO stock trades near $10 currently and it is, in fact, down 27% fr